Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
USPIO-enhanced high-field MRI for restaging lymph node status in rectal cancer
2016-002588-32Phase 3Completed
- Sponsor
- Radboudumc
- Start
- Aug 2016
- Modality
- Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ferumoxtran-10 in rectal cancer, sponsored by Radboudumc. Primary endpoint: Sensitivity and specificity of 7T MRI with USPIO enhancement for lymph node metastasis detection. Started Aug 2016; status: completed.
02
Drugs
ferumoxtran-10
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2016-002588-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002588-32.